All invasive nontyphoidal Salmonella articles
-
NewsCARB‑X–supported trivalent Salmonella vaccine advances to Phase 2 clinical trials
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced that GSK’s global health vaccine program for a combined invasive nontyphoidal Salmonella and typhoid fever (iNTS‑TCV) has advanced into a Phase 2 clinical trial.